GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (STU:TCE2) » Definitions » Other Financing

Celldex Therapeutics (STU:TCE2) Other Financing : €3.51 Mil (TTM As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Celldex Therapeutics Other Financing?

Celldex Therapeutics's Other Financing for the three months ended in Mar. 2024 was €3.51 Mil.

Celldex Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2024 was €3.51 Mil.

Celldex Therapeutics Other Financing Historical Data

The historical data trend for Celldex Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics Other Financing Chart

Celldex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.36 2.19 - 2.05

Celldex Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 3.51

Celldex Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics Other Financing Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Celldex Therapeutics (STU:TCE2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (STU:TCE2) » Definitions » Other Financing
Comparable Companies
ARVN NTLA SMMT ACAD JANX VCEL MLTX TGTX FTRE NVAX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
CLDX:USA
Address
53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Website
https://www.celldex.com
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Celldex Therapeutics (STU:TCE2) Headlines

No Headlines